# Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer

> **NCT02739529** · PHASE1 · UNKNOWN · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 18 (estimated)

## Conditions studied

- Gynecologic Cancer

## Interventions

- **DRUG:** Genexol-PM

## Key facts

- **NCT ID:** NCT02739529
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739529, "Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02739529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*